BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 11435790)

  • 21. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Bezard E; Dovero S; Prunier C; Ravenscroft P; Chalon S; Guilloteau D; Crossman AR; Bioulac B; Brotchie JM; Gross CE
    J Neurosci; 2001 Sep; 21(17):6853-61. PubMed ID: 11517273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concentration and occupancy of dopamine transporters in cocaine abusers with [11C]cocaine and PET.
    Logan J; Volkow ND; Fowler JS; Wang GJ; Fischman MW; Foltin RW; Abumrad NN; Vitkun S; Gatley SJ; Pappas N; Hitzemann R; Shea CE
    Synapse; 1997 Dec; 27(4):347-56. PubMed ID: 9372557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential of [(18)F]beta-CFT-FE (2beta-carbomethoxy-3beta-(4-fluorophenyl)-8-(2-[(18)F]fluoroethyl)nortropane) as a dopamine transporter ligand: A PET study in the conscious monkey brain.
    Harada N; Ohba H; Fukumoto D; Kakiuchi T; Tsukada H
    Synapse; 2004 Oct; 54(1):37-45. PubMed ID: 15300883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study.
    Burn DJ; Brooks DJ
    Neurology; 1993 Mar; 43(3 Pt 1):552-6. PubMed ID: 8451000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling analysis of [11C]flumazenil kinetics studied by PET: application to a critical study of the equilibrium approaches.
    Delforge J; Syrota A; Bottlaender M; Varastet M; Loc'h C; Bendriem B; Crouzel C; Brouillet E; Maziere M
    J Cereb Blood Flow Metab; 1993 May; 13(3):454-68. PubMed ID: 8478404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys.
    Guttman M; Yong VW; Kim SU; Calne DB; Martin WR; Adam MJ; Ruth TJ
    Synapse; 1988; 2(5):469-73. PubMed ID: 3263709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
    Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
    Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 6-[18F]fluoro-L-dopa uptake and [76Br]bromolisuride binding in the excitotoxically lesioned caudate-putamen of nonhuman primates studied using positron emission tomography.
    Hantraye P; Loc'H C; Maziere B; Khalili-Varasteh M; Crouzel C; Fournier D; Yorke JC; Stulzaft O; Riche D; Isacson O
    Exp Neurol; 1992 Feb; 115(2):218-27. PubMed ID: 1531196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
    Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
    J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
    Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
    Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.
    Frost JJ; Rosier AJ; Reich SG; Smith JS; Ehlers MD; Snyder SH; Ravert HT; Dannals RF
    Ann Neurol; 1993 Sep; 34(3):423-31. PubMed ID: 8363363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters.
    Goodman MM; Kilts CD; Keil R; Shi B; Martarello L; Xing D; Votaw J; Ely TD; Lambert P; Owens MJ; Camp VM; Malveaux E; Hoffman JM
    Nucl Med Biol; 2000 Jan; 27(1):1-12. PubMed ID: 10755640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and 18F-Dopa uptake and metabolism after intracerebral implantation in nonhuman primates.
    Subramanian T; Emerich DF; Bakay RA; Hoffman JM; Goodman MM; Shoup TM; Miller GW; Levey AI; Hubert GW; Batchelor S; Winn SR; Saydoff JA; Watts RL
    Cell Transplant; 1997; 6(5):469-77. PubMed ID: 9331498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
    Ouattara B; Gasparini F; Morissette M; Grégoire L; Samadi P; Gomez-Mancilla B; Di Paolo T
    J Neurochem; 2010 May; 113(3):715-24. PubMed ID: 20132464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter.
    Schou M; Steiger C; Varrone A; Guilloteau D; Halldin C
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4843-5. PubMed ID: 19577467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
    Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
    Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[β-(11)C]DOPA and [(18)F]FE-PE2I in humans.
    Suzuki M; Ito H; Kodaka F; Takano H; Kimura Y; Fujiwara H; Sasaki T; Takahata K; Nogami T; Nagashima T; Nengaki N; Kawamura K; Zhang MR; Varrone A; Halldin C; Okubo Y; Suhara T
    Nucl Med Commun; 2014 Mar; 35(3):231-7. PubMed ID: 24468851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.
    Andringa G; Drukarch B; Bol JG; de Bruin K; Sorman K; Habraken JB; Booij J
    Neuroimage; 2005 Jul; 26(4):1150-8. PubMed ID: 15908232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.